

\*\*\*\*Published October 2014\*\*\*\*

## MarketVIEW: MMR, MMRV and varicella vaccines

<b>Product Name</b>	:	<b>MarketVIEW: MMR, MMRV and varicella vaccines</b>
<b>Description</b>	:	Global vaccine commercial opportunity assessment
<b>Contents</b>	:	Executive presentation + 1 forecast model(s)
<b>Therapeutic Area</b>	:	Pediatric vaccines
<b>Publication date</b>	:	October 2014
<b>Catalogue No</b>	:	VAMV058

### Background

Measles, mumps and rubella can cause severe morbidity or even death in young children in underdeveloped countries. Because combination MMR vaccines (licensed since 1971) have led to a >99% reduction in these diseases in the US the WHO seeks to control these diseases globally. Example programs are the Measles & Rubella Initiative which has reduced global measles deaths from ~562,000 in 2000 to 122,000 in 2012 (mostly children <5yrs). The WHO recommends that two doses of measles vaccine are included in national immunization programmes (NIPs), one dose of rubella vaccine with varying policies/roll out on triple combination vaccines. For varicella, another important childhood disease a limited number of countries have added varicella vaccines to NIPs sometimes through MMRV.

This **MarketVIEW** product is a comprehensive commercial opportunity assessment detailing the potential market for MMR, MMRV and varicella vaccines (doses 000s, \$ 000s) to 2030 across Western markets, LATAM and key ROW markets. The forecast takes into account the introduction of new national immunization programs (NIPs) for varicella, launch of new products e.g. GSK's Priorix (US) and provides revenues per major competitor. Country specific dynamics with detailed vaccine coverage assumptions, doses variance are included along with description of future developments in GAVI/ROW countries.

## Methodology

**VacZine Analytics** has closely monitored all significant source material pertaining to MMR, MMRV and varicella vaccines. Example, secondary source materials used are literature articles, government websites/databases, medical bodies and associations, conference proceedings and previously analyses (where publically available). Previously published research by **VacZine Analytics** in field of pediatric vaccines has also been utilised. \*\*\***See Bibliography for exact sources.**

### PRODUCT CONTENTS:

**Published October 2014 (CAT No: VAMV058)**

\*\*\*\*This product is composed of a model and summary presentation

#### **Contents – Summary presentation (MS PowerPoint based)**

- Author's note
- Executive Summary
- Commercial model key outputs
- MMRV vaccine family: global sales by vaccine (\$m) to 2030
- MMRV vaccine family: global sales by region (\$m) to 2030
- MMRV vaccine family: global sales by company (\$m) to 2030
- MMRV vaccine family: global sales, Merck & Co (\$m) to 2030
- MMRV vaccine family: US sales, Merck & Co (\$m) to 2030
- MMRV vaccine family: global value, GlaxoSmithKline (\$m) to 2030
- Major model assumptions
- Markets included in model
- Vaccines included in model
- Country inputs
- MMR vaccine inputs
- Varicella vaccine inputs
- Background and epidemiology of measles
- Background and epidemiology of mumps
- Background and epidemiology of rubella
- Background and epidemiology of varicella
- Country vaccine recommendations
- Measles vaccine: national immunization programmes, 2013
- Mumps vaccine: national immunization programmes, 2012
- Rubella vaccine: national immunization programmes, 2012
- Vaccine schedules: WHO goals
- Varicella vaccination in Europe
- Varicella vaccination recommendations in Europe, 2012
- Febrile seizures: MMRV combination vaccines (ProQuad and Priorix-Tetra)
- MMRV family vaccines – licensed vaccines
- Merck & Co and GlaxoSmithKline vaccines
- WHO prequalified vaccines
- Company reported sales
- Coverage rates
- Future trends: GlaxoSmithKline's US approval of Priorix
- Future trends: addition of varicella vaccine to NIPs

**Continued...**

Future trends: bivalent measles/rubella (MR) vaccines

Disclaimer

About **VacZine Analytics**

**PAGES: 65 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form**

**Contents – Vaccine demand model(s) (MS Excel-based) – 1 model**

Title sheet

Charts - Total Vol and Val

Merck & Co sales

GSK sales

Merck & Co – market share

GSK – market share

Value

Value by region

Volume

Country models

USA

CANADA

FRANCE

ITALY

SPAIN

GERMANY

OTHER EUROPE

MIDDLE EAST

BRAZIL

MEXICO

OTHER LATAM

AUSTRALIA

RUSSIA

JAPAN

SOUTH KOREA

TURKEY

DATA SOURCES

Populations

1 yrs

5 yrs

MMR summary

Varicella summary

Priority MR countries

Income groups

Pub/priv split

Measles

MR

MMR

Varicella

Merck Reported sales

**WORKSHEETS: ~37**

## PRODUCT COST:

**VacZine Analytics** will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD **\$8995.00**/ GBP **£5695.00**<sup>#</sup> (Region license)\*
- PRESENTATION OR MODEL ONLY - USD **\$4995.00** (Region license)\*

<sup>#</sup> Indicative rate only. Prevailing rate applied to date of transaction.

\*A region is North America, Europe or ROW

For orders in the UK, VAT at 20.0% will be added to final invoice total

## HOW TO ORDER:

To order please contact your region account manager or order direct at [orders@vaczine-analytics.com](mailto:orders@vaczine-analytics.com)

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



**VacZine Analytics (R)** is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics (R)** and the “**spiral logo**” are UK Registered Trademarks, 2009

## BIBLIOGRAPHY:

1. CBER Clinical Review Of Studies Submitted In Support Of Licensure Of ProQuad. Available at: <http://www.fda.gov/>. Accessed: October 2014
2. European Centre for Disease Prevention and Control. Factsheet for health professionals. Available at: <http://www.ecdc.europa.eu/>. Accessed: October 2014
3. Prevention of Measles, Rubella, Congenital Rubella Syndrome, and Mumps, 2013: Summary Recommendations of the Advisory Committee on Immunization Practices (ACIP). Available at: <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6204a1.htm>. Accessed: October 2014
4. Measles & Rubella Initiative. Available at: <http://www.measlesrubellainitiative.org/>. Accessed: October 2014.
5. WHO. Immunization surveillance, assessment and monitoring. Available at: [http://apps.who.int/immunization\\_monitoring/diseases/measles/en/index.html](http://apps.who.int/immunization_monitoring/diseases/measles/en/index.html). Accessed: October 2014.
6. WHO position papers. Weekly epidemiological record. No. 7, 2007, 82, 49–60.
7. Global Overview of Measles & Rubella. 11th Annual Meeting. The Measles Initiative Washington, DC, 18-19th September, 2012
8. Global Rubella Update and Incorporating MR vaccine Into National Immunizations Programs. 13<sup>th</sup> Annual Meeting American Red Cross National Headquarters. September 9, 2014.
9. European Centre for Disease Prevention and Control. Varicella vaccine in the European, 2014.
10. Varicella disease burden and varicella vaccine. Available at [http://www.who.int/immunization/sage/meetings/2014/april/2\\_SAGE\\_April\\_VZV\\_Seward\\_Varicella.pdf](http://www.who.int/immunization/sage/meetings/2014/april/2_SAGE_April_VZV_Seward_Varicella.pdf). Accessed October 2014.
11. Varicella and herpes zoster vaccines: WHO position paper, June 2014. Available at: <http://www.who.int/wer/2014/wer8925.pdf>. Accessed: October 2014
12. WHO. Immunization surveillance, assessment and monitoring. Available at: [http://gamapserver.who.int/gho/interactive\\_charts/immunization/mcv/atlas.html](http://gamapserver.who.int/gho/interactive_charts/immunization/mcv/atlas.html). Accessed: October 2014.
13. Piano Nazionale Prevenzione Vaccinale (PNPV) 2012 – 2014. Available at: <http://www.sanita.puglia.it/portal/page/portal/SAUSSC/Prevenzione/Vaccinazioni/PNV.pdf>. Accessed: October 2014.
14. Marin M et al. Use of combination measles, mumps, rubella, and varicella vaccine. MMWR Recomm Rep. 2010 May 7;59(RR-3):1-12.
15. MacDonald SE et al. Risk of febrile seizures after first dose of measles-mumps-rubella-varicella vaccine: a population-based cohort study. CMAJ. 2014 Aug 5;186(11):824-9.
16. VENICE. Varicella and herpes zoster surveillance and vaccination recommendations. 2011. Available at: [http://venice.cineca.org/report\\_final\\_varicella.pdf](http://venice.cineca.org/report_final_varicella.pdf). Accessed: October 2014.
17. Measles-containing vaccines (MCVs) market update. December 2013. Available at: [http://www.unicef.org/supply/files/Measles-Containing\\_Vaccines\\_\(MCV\)\\_Supply\\_Update\\_May\\_2014.pdf](http://www.unicef.org/supply/files/Measles-Containing_Vaccines_(MCV)_Supply_Update_May_2014.pdf). Accessed August 2014.
18. Brazil To Produce Low-Cost Measles & Rubella Vaccine For Poor Countries. Available at: <http://www.economywatch.com/news/brazil-measles-rubella-vaccine.29-10.html>. Accessed: October 2014.
19. Sanofi MSD. Our Vaccines. Available at: <http://www.spmtd.com/our-vaccines/>. Accessed: October 2014.
20. China Measles, Mumps and Rubella Vaccine Market (MMR). Thursday, September 19, 2013. Available at: <http://beforeitsnews.com/china/2013/09/china-measles-mumps-and-rubella-vaccine-market-mmr-2447406.html>. Accessed: October 2014.
21. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2013. MMWR July 25, 2014 / 63(29):625-33. Available at: <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6329a4.htm>. Accessed: October 2014
22. Lopez AS et al. Two-dose varicella vaccination coverage among children aged 7 years--six sentinel sites, United States, 2006-2012. MMWR Morb Mortal Wkly Rep. 2014 Feb 28;63(8):174-7.
23. VENICE. Varicella and herpes zoster surveillance and vaccination recommendations.2011. Available at: [http://venice.cineca.org/report\\_final\\_varicella.pdf](http://venice.cineca.org/report_final_varicella.pdf). Accessed: October 2014.
24. European Vaccine Action Plan 2015–2020. Available at: <http://www.euro.who.int/>. Accessed: October 2014
25. Kurugol Z et al. Varicella rates among unvaccinated and one-dose vaccinated healthy children in Izmir, Turkey. Int J Infect Dis. 2011 Jul;15(7):e475-80.
26. Over 700 million children in 49 countries to be protected against measles and rubella. Available at: <http://www.gavi.org/Library/News/Press-releases/2013/Over-700-million-children-in-49-countries-to-be-protected-against-measles-and-rubella/>. Accessed: October 2014.

## TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according to the description proposed by the Company.
3. **Cancellation policy.** The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. **Force Majeure:** The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

### VacZine Analytics

Warren House  
Bells Hill  
Bishops Stortford  
Herts  
CM23 2NN  
Spain  
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926  
E-mail: [info@vacZine-analytics.com](mailto:info@vacZine-analytics.com)

## About VacZine Analytics:

**VacZine Analytics** is an established strategic research agency based in the Spain. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website [www.vacZine-analytics.com](http://www.vacZine-analytics.com)

**VacZine Analytics (R)** is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics (R)** and “the spiral logo” are UK Registered Trademarks, 2009

Follow us on Twitter **@vaczineanalytic**

Signup to our newsletter ExpertREACT - <http://www.vacZine-analytics.com/products-expertreact.asp>

Signup to our free vaccine pipeline database - <http://www.vaccinestats.com>